GlassScriptPhysician profile
Krista Brown
NPI 1629435177
$2,959.62
in general payments reported to CMS, 2019-2025
26 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $508 · 2024: $1,392 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.17 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $505.40 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $232.06 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $231.76 | 2023-2024 | Xarelto |
| Lilly USA, LLC | $178.05 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $159.74 | 2024-2025 | |
| Napo Pharmaceuticals INC | $133.21 | 2023 | Mytesi |
| Exact Sciences Corporation | $130.13 | 2023-2024 | Cologuard Collection Kit |
| Lexicon Pharmaceuticals, INC. | $124.99 | 2023 | Inpefa |
| Aimmune Therapeutics, INC. | $122.08 | 2024 | |
| Alnylam Pharmaceuticals INC. | $121.84 | 2025 | Amvuttra |
| Pfizer INC. | $84.45 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $53.95 | 2024 | |
| Gilead Sciences, INC. | $46.34 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.44 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $41.44 | 2024 | Skyclarys |
| Abbvie INC. | $41.16 | 2025 | |
| Astellas Pharma US INC | $40.94 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $27.50 | 2025 | Vpriv |
| Dexcom, INC. | $24.56 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $21.31 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.75 | 2024 | Jardiance |
| Sumitomo Pharma America, INC. | $19.20 | 2023 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $19.15 | 2025 | Strensiq |
| Esperion Therapeutics, INC. | $14.82 | 2023 | Nexletol |
| Axsome Therapeutics, INC. | $14.18 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.